Clinical Trials Search Results
Results 1-10 of 125 for your search
Show Search Criteria
Your Search Criteria
Category |
Your Selection |
|---|---|
| Keywords/Phrases: | "endometrial cancer" |
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 1174 locations
Age: 18 years and over
Gender: Male or Female
Location: 1174 locations
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 845 locations
Age: 18 years and over
Gender: Male or Female
Location: 845 locations
Olaparib and Cediranib Maleate in Treating Patients with Recurrent, Refractory, or Metastatic Endometrial Cancer
Status: Active
Age: 18 years and over
Gender: Female
Location: 591 locations
Age: 18 years and over
Gender: Female
Location: 591 locations
Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer
Status: Active
Age: Not specified
Gender: Female
Location: 318 locations
Age: Not specified
Gender: Female
Location: 318 locations
Cabozantinib and Nivolumab in Treating Patients with Advanced, Recurrent or Metastatic Endometrial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 33 locations
Age: 18 years and over
Gender: Male or Female
Location: 33 locations
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 35 locations
Age: 18 years and over
Gender: Male or Female
Location: 35 locations
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Age: 18 years and over
Gender: Female
Location: 26 locations
Age: 18 years and over
Gender: Female
Location: 26 locations
Neratinib HER Mutation Basket Study (SUMMIT)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 18 locations
Age: 18 years and over
Gender: Male or Female
Location: 18 locations
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 13 locations
Age: 18 years and over
Gender: Male or Female
Location: 13 locations